Status:
COMPLETED
Nigella Sativa in COVID-19
Lead Sponsor:
King Abdulaziz University
Conditions:
COVID-19
SARS-CoV-2
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Natural products with immunomodulation and antiviral activity showed a promising improvement in the outcomes of some viral infectious diseases both in preclinical and primitive clinical studies. The a...
Eligibility Criteria
Inclusion
- Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia
- Adult (18 Years and above)
- Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative).
- Understands and agrees to comply with planned study procedures.
- Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH.
Exclusion
- Patients with pneumonia or severe illness requiring admission to ICU.
- Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \< 30) or end stage renal disease requiring dialysis
- Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \> 5 times the upper limit of normal).
- Pregnancy or breast feeding.
- Anticipated transfer to another hospital which is not a study site within 72 hours.
- Allergy to any study medication.
Key Trial Info
Start Date :
May 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT04401202
Start Date
May 21 2020
End Date
December 31 2020
Last Update
May 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Abdulaziz University Hospital
Jeddah, Saudi Arabia, 21589